Karyopharm Therapeutics Inc. 8-K

What Happened
Karyopharm Therapeutics Inc. announced preliminary, unaudited financial estimates in an 8-K filed January 12, 2026 (Exhibit 99.1). The company reported estimated total revenue of ~$33 million for Q4 2025 and ~$145 million for full-year 2025, driven largely by U.S. net product sales of XPOVIO (selinexor). Karyopharm also reported approximately $64 million in cash, cash equivalents, restricted cash and investments as of December 31, 2025, and said its existing liquidity plus expected XPOVIO and license revenues should fund operations into Q2 2026.

Key Details

• Preliminary total revenue: ~ $33M (Q4 2025); ~ $145M (FY 2025).
• Preliminary U.S. XPOVIO net product revenue: ~ $32M (Q4 2025); ~ $115M (FY 2025).
• Preliminary cash, cash equivalents, restricted cash and investments: ~ $64M as of 12/31/2025.
• Company states liquidity is expected to fund planned operations into Q2 2026; figures are unaudited and subject to financial close and review by auditors.

Why It Matters
These preliminary results give investors an early view of Karyopharm’s revenue mix and near-term liquidity. XPOVIO sales appear to be the primary revenue driver in 2025, and the reported cash balance and stated runway into Q2 2026 are key facts for assessing the company’s near-term financing and operational needs. Note these numbers are management estimates and unaudited; the independent auditor has not reviewed or provided assurance on them.